Investor Eye: Juno Capital Believes Medtech Is An Optimal Long-Term Investment
Juno Capital partner Edward Rudd believes that investing in medtech offers not only a long-term strategy for allocating capital, but an altruistic relief for investors.
You may also be interested in...
As the value of medtech deals increases, investors are increasingly looking for earlier opportunities. COVID-19 has added both impetus and new opportunity, with innovators and investors vying to build a position in digital health technologies, such as remote monitoring and digital therapeutics.
Unmet needs are at the core of Endeavour Vision’s investment strategy, accepting that payment models may need to change as patients become more directly involved in device development.
A new report from Informa's Meddevicetracker highlights strong projected growth in the market, explaining the underlying reasons why.